Diplomat Pharmacy Inc (NYSE:DPLO)’s share price rose 10.7% during mid-day trading on Monday after Needham & Company LLC raised their price target on the stock from $24.00 to $26.00. Needham & Company LLC currently has a buy rating on the stock. Diplomat Pharmacy traded as high as $23.08 and last traded at $22.99. Approximately 2,577,700 shares were traded during trading, an increase of 145% from the average daily volume of 1,050,375 shares. The stock had previously closed at $20.77.

Several other equities analysts also recently issued reports on the stock. Robert W. Baird downgraded shares of Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $24.00 to $18.00 in a report on Thursday, November 16th. BidaskClub downgraded shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. Deutsche Bank started coverage on shares of Diplomat Pharmacy in a report on Monday, December 4th. They set a “buy” rating and a $22.00 price objective on the stock. Mizuho increased their target price on shares of Diplomat Pharmacy from $16.00 to $20.00 and gave the company a “neutral” rating in a research report on Tuesday, November 7th. Finally, Leerink Swann upgraded shares of Diplomat Pharmacy from a “market perform” rating to an “outperform” rating and set a $23.00 target price for the company in a research report on Monday, December 11th. Five research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $20.94.

In other Diplomat Pharmacy news, CFO Atul Kavthekar bought 2,000 shares of Diplomat Pharmacy stock in a transaction dated Monday, November 20th. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $30,000.00. Following the completion of the transaction, the chief financial officer now directly owns 2,000 shares of the company’s stock, valued at $30,000. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey G. Park bought 3,000 shares of Diplomat Pharmacy stock in a transaction dated Monday, November 20th. The stock was acquired at an average price of $15.46 per share, with a total value of $46,380.00. Following the completion of the transaction, the director now directly owns 7,640 shares of the company’s stock, valued at $118,114.40. The disclosure for this purchase can be found here. Insiders bought 15,000 shares of company stock valued at $228,780 over the last quarter. Company insiders own 30.20% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. increased its position in Diplomat Pharmacy by 46.7% during the second quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock worth $130,000 after purchasing an additional 2,794 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Diplomat Pharmacy during the third quarter worth about $191,000. Piedmont Investment Advisors LLC acquired a new stake in Diplomat Pharmacy during the third quarter worth about $216,000. First Allied Advisory Services Inc. acquired a new stake in Diplomat Pharmacy during the second quarter worth about $183,000. Finally, Invictus RG increased its position in Diplomat Pharmacy by 24.4% during the third quarter. Invictus RG now owns 13,820 shares of the company’s stock worth $286,000 after purchasing an additional 2,707 shares during the last quarter. Institutional investors and hedge funds own 72.21% of the company’s stock.

The firm has a market cap of $1,600.00, a PE ratio of 197.25, a PEG ratio of 3.62 and a beta of 0.62. The company has a quick ratio of 0.82, a current ratio of 1.34 and a debt-to-equity ratio of 0.18.

Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings data on Monday, November 6th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a net margin of 0.18% and a return on equity of 8.30%. The firm had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same period last year, the business earned $0.21 earnings per share. Diplomat Pharmacy’s revenue was down 4.8% compared to the same quarter last year. sell-side analysts predict that Diplomat Pharmacy Inc will post 0.85 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/diplomat-pharmacy-dplo-stock-price-up-10-7-after-analyst-upgrade/1800522.html.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with Analyst Ratings Network's FREE daily email newsletter.